According to the Medication Guide on the Actos website regarding bladder cancer—Preclinical and clinical trial data, and results from an observational study suggest an increased risk of bladder cancer in pioglitazone (Actos) users.
The observational data further suggest that the risk increases with duration of use. Do not use in patients with active bladder cancer. Take caution when using in patients with a prior history of bladder cancer.
The Actos website claims: There are insufficient data to determine whether pioglitazone (Actos) is a tumor promoter for urinary bladder tumors.
However a FDA warning exists about the possible causal relationship between Actos and related bladder cancer. That communication alert was published June 15, 2011. The Actos label changed almost two months later.
Can I file a claim for Actos related bladder cancer?
Yes, you can file if you were diagnosed with bladder cancer and took Actos for a year or more. You are not alone as Actos users with bladder cancer are doing just that.
There are many claims filed for unsafe drugs – Actos is just one of them.
Is the FDA doing their job? A drug manufacturer (Actos is made by Takeda Pharmaceutical Company) conducts its own studies and controls the information that it provides to the FDA. This is an honor system way of doing business. Who can you trust? After a drug is approved for sale, it is the drug maker’s responsibility to report adverse effects and side affects to the FDA.
There needs to be a better system with more oversight and more consumer protections.
Until then, if you have been diagnosed with bladder cancer and have been taking Actos or an Actos derivative drug, then you may be entitled to file a claim for Actos related bladder cancer.